tiprankstipranks
Staar Surgical Company (CH:SR3)
NASDAQ:SR3
Switzerland Market
SR3
Staar Surgical
RESEARCH TOOLSreports

Staar Surgical (SR3) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

SR3 Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
2 Buy
5 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Staar
Surgical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SR3 Stock 12 Month Forecast

Average Price Target

$26.43
Based on 7 Wall Street analysts offering 12 month price targets for Staar Surgical in the last 3 months. The average price target is $26.43 with a high forecast of $32.43 and a low forecast of $21.89. The average price target represents a ― change from the last price of ―.
eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
Highest Price Target$32.43Average Price Target$26.43Lowest Price Target$21.89
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on CH:SR3
Michael Piccolo
Wedbush
Wedbush
CHF32.43
Buy
―
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on CH:SR3
John Young CFA
Canaccord Genuity
Canaccord Genuity
CHF25.94
Buy
―
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Cogent Biosciences (NASDAQ: COGT) and GlaxoSmithKline (NYSE: GSK)
Piper Sandler Analyst forecast on CH:SR3
Adam Maeder
Piper Sandler
Piper Sandler
CHF12.97→CHF26.75
Hold
―
Reiterated
05/14/26
Staar Surgical price target raised to $33 from $16 at Piper SandlerStaar Surgical price target raised to $33 from $16 at Piper Sandler
Mizuho Securities Analyst forecast on CH:SR3
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF17.83→CHF21.89
Hold
―
Reiterated
05/14/26
Staar Surgical price target raised to $27 from $22 at MizuhoStaar Surgical price target raised to $27 from $22 at Mizuho
Stifel Nicolaus Analyst forecast on CH:SR3
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
CHF14.59→CHF25.13
Hold
―
Reiterated
05/14/26
Staar Surgical price target raised to $31 from $18 at StifelStaar Surgical price target raised to $31 from $18 at Stifel
BTIG Analyst forecast on CH:SR3
Ryan Zimmerman
BTIG
BTIG
―
Hold
―
Reiterated
05/14/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (NASDAQ: STAA), Halozyme (NASDAQ: HALO) and Vor Biopharma (NASDAQ: VOR)
Needham Analyst forecast on CH:SR3
David Saxon
Needham
Needham
―
Hold
―
Reiterated
05/14/26
Analyst Maintains Hold on Staar Surgical Amid Stable Trends but Limited Visibility Into 2026 Outlook
Morgan Stanley Analyst forecast on CH:SR3
Patrick Wood
Morgan Stanley
Morgan Stanley
CHF10.54
Sell
―
Reiterated
03/11/26
Morgan Stanley Reaffirms Their Sell Rating on Staar Surgical (STAA)
Stephens Analyst forecast on CH:SR3
Unknown Analyst
Stephens
Not Ranked
Stephens
CHF22.7
Hold
―
Reiterated
03/04/26
Stephens Sticks to Its Hold Rating for Staar Surgical (STAA)
Jefferies Analyst forecast on CH:SR3
Raj Denhoy
Jefferies
Jefferies
CHF17.02→CHF22.7
Hold
―
Reiterated
08/06/25
Jefferies Remains a Hold on Staar Surgical (STAA)
Sidoti Analyst forecast on CH:SR3
James Sidoti
Sidoti
Sidoti
CHF21.89→CHF22.7
Hold
―
Downgraded
08/05/25
Staar Surgical downgraded to Neutral from Buy at SidotiStaar Surgical downgraded to Neutral from Buy at Sidoti
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on CH:SR3
Michael Piccolo
Wedbush
Wedbush
CHF32.43
Buy
―
Reiterated
05/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on CH:SR3
John Young CFA
Canaccord Genuity
Canaccord Genuity
CHF25.94
Buy
―
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Cogent Biosciences (NASDAQ: COGT) and GlaxoSmithKline (NYSE: GSK)
Piper Sandler Analyst forecast on CH:SR3
Adam Maeder
Piper Sandler
Piper Sandler
CHF12.97→CHF26.75
Hold
―
Reiterated
05/14/26
Staar Surgical price target raised to $33 from $16 at Piper SandlerStaar Surgical price target raised to $33 from $16 at Piper Sandler
Mizuho Securities Analyst forecast on CH:SR3
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF17.83→CHF21.89
Hold
―
Reiterated
05/14/26
Staar Surgical price target raised to $27 from $22 at MizuhoStaar Surgical price target raised to $27 from $22 at Mizuho
Stifel Nicolaus Analyst forecast on CH:SR3
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
CHF14.59→CHF25.13
Hold
―
Reiterated
05/14/26
Staar Surgical price target raised to $31 from $18 at StifelStaar Surgical price target raised to $31 from $18 at Stifel
BTIG Analyst forecast on CH:SR3
Ryan Zimmerman
BTIG
BTIG
―
Hold
―
Reiterated
05/14/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (NASDAQ: STAA), Halozyme (NASDAQ: HALO) and Vor Biopharma (NASDAQ: VOR)
Needham Analyst forecast on CH:SR3
David Saxon
Needham
Needham
―
Hold
―
Reiterated
05/14/26
Analyst Maintains Hold on Staar Surgical Amid Stable Trends but Limited Visibility Into 2026 Outlook
Morgan Stanley Analyst forecast on CH:SR3
Patrick Wood
Morgan Stanley
Morgan Stanley
CHF10.54
Sell
―
Reiterated
03/11/26
Morgan Stanley Reaffirms Their Sell Rating on Staar Surgical (STAA)
Stephens Analyst forecast on CH:SR3
Unknown Analyst
Stephens
Not Ranked
Stephens
CHF22.7
Hold
―
Reiterated
03/04/26
Stephens Sticks to Its Hold Rating for Staar Surgical (STAA)
Jefferies Analyst forecast on CH:SR3
Raj Denhoy
Jefferies
Jefferies
CHF17.02→CHF22.7
Hold
―
Reiterated
08/06/25
Jefferies Remains a Hold on Staar Surgical (STAA)
Sidoti Analyst forecast on CH:SR3
James Sidoti
Sidoti
Sidoti
CHF21.89→CHF22.7
Hold
―
Downgraded
08/05/25
Staar Surgical downgraded to Neutral from Buy at SidotiStaar Surgical downgraded to Neutral from Buy at Sidoti
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Staar Surgical

3 Months
Patrick WoodMorgan Stanley
Success Rate
4/7 ratings generated profit
57%
Average Return
-0.06%
Copying Patrick Wood's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of -0.06% per trade.
1 Year
Patrick WoodMorgan Stanley
Success Rate
4/7 ratings generated profit
57%
Average Return
-2.09%
Copying Patrick Wood's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -2.09% per trade.
2 Years
Patrick WoodMorgan Stanley
Success Rate
3/7 ratings generated profit
43%
Average Return
-21.31%
Copying Patrick Wood's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -21.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SR3 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
0
0
1
5
5
Hold
13
19
19
20
10
Sell
1
2
1
1
0
Strong Sell
0
0
0
0
0
total
14
21
21
26
15
In the current month, SR3 has received 5 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. SR3 average Analyst price target in the past 3 months is 26.43.
Each month's total comprises the sum of three months' worth of ratings.

SR3 Financial Forecast

SR3 Earnings Forecast

Next quarter’s earnings estimate for SR3 is $0.18 with a range of $0.04 to $0.27. The previous quarter’s EPS was $0.32. SR3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SR3 has Performed in-line its overall industry.
Next quarter’s earnings estimate for SR3 is $0.18 with a range of $0.04 to $0.27. The previous quarter’s EPS was $0.32. SR3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SR3 has Performed in-line its overall industry.

SR3 Sales Forecast

Next quarter’s sales forecast for SR3 is $71.17M with a range of $68.43M to $77.51M. The previous quarter’s sales results were $73.82M. SR3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SR3 has Performed in-line its overall industry.
Next quarter’s sales forecast for SR3 is $71.17M with a range of $68.43M to $77.51M. The previous quarter’s sales results were $73.82M. SR3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SR3 has Performed in-line its overall industry.

SR3 Stock Forecast FAQ

What is CH:SR3’s average 12-month price target, according to analysts?
Based on analyst ratings, Staar Surgical Company’s 12-month average price target is 26.43.
    What is CH:SR3’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:SR3, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Staar Surgical Company a Buy, Sell or Hold?
        Staar Surgical Company has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 5 hold ratings and 0 sell ratings.
          What is Staar Surgical Company’s share price target?
          The average share price target for Staar Surgical Company is 26.43. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $32.43 ,and the lowest forecast is $21.89. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Staar Surgical Company?
            Staar Surgical Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
              How can I buy shares of Staar Surgical Company?
              To buy shares of CH:SR3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.